Cellectar’s Iopofosine I 131 Earns Rare Pediatric Disease Designation, Shows Strong Survival Benefit in Aggressive Brain Tumors
Market Chameleon (Mon, 27-Oct 8:52 AM)
EMA Eligibility Paves Way for Cellectar's Iopofosine I 131 in Treating Refractory WM Across Europe
Market Chameleon (Mon, 6-Oct 8:22 AM)
